Comparative Pharmacology
Head-to-head clinical analysis: FOSCAVIR versus RIMANTADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSCAVIR versus RIMANTADINE HYDROCHLORIDE.
FOSCAVIR vs RIMANTADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Foscarnet is a pyrophosphate analog that selectively inhibits viral DNA polymerase and reverse transcriptase by binding to the pyrophosphate binding site, preventing the cleavage of pyrophosphate from deoxynucleotide triphosphates, thereby inhibiting viral DNA synthesis. It does not require activation by viral thymidine kinase, making it active against acyclovir-resistant HSV and VZV, and ganciclovir-resistant CMV.
Rimantadine is a tricyclic amine antiviral that inhibits influenza A virus replication by blocking the M2 proton ion channel, preventing viral uncoating and release of viral RNA into host cells.
Induction: 60 mg/kg IV every 8 hours for 2-3 weeks, then maintenance: 90-120 mg/kg IV once daily. Administer as a 2-hour infusion via central line.
100 mg orally twice daily for 7 days; initiate within 48 hours of symptom onset.
None Documented
None Documented
Terminal elimination half-life is approximately 3-5 hours in patients with normal renal function; can extend to 48-120 hours in severe renal impairment (CrCl <20 mL/min), requiring dose adjustment and therapeutic drug monitoring.
25.4 hours (range 13–65 h); prolonged in elderly (38 h) and severe renal impairment (CrCl <10 mL/min: up to 130 h).
Primarily renal excretion (>80% as unchanged drug) via glomerular filtration and tubular secretion; minimal biliary/fecal elimination (<5%).
Renal: 75% unchanged; fecal: <10%; biliary: minimal. Total clearance 2.5 mL/min/kg.
Category C
Category A/B
Antiviral
Antiviral